Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
The purpose of this study is to evaluate the combination of Revlimid速 (lenalidomide) and Nexavar速 (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.
Hepatocellular Carcinoma
DRUG: Lenalidomide|DRUG: Sorafenib
Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib., 2 years
The purpose of this study is to evaluate the combination of Revlimid速 (lenalidomide) and Nexavar速 (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.